CTT Pharmaceutical Holdings CEO Ryan Khouri purchased 2,100 shares of common stock on Aug. 24 at $0.055 per share, totaling $115, according to a Form 4 filing with the U.S. Securities and Exchange Commission.
The transaction occurred as CTT Pharmaceutical’s stock traded near $0.06, reflecting a modest valuation for the micro-cap company. Khouri’s direct holdings in the firm now stand at 9,360,756 shares.
CTT Pharmaceutical, which operates under the NASDAQ ticker CTTH, has a market capitalization of $3.35 million. Despite reporting a 63% return over the past year, the company remains unprofitable over the last twelve months, according to InvestingPro data. The firm’s financial health rating is classified as "FAIR," and its valuation is flagged as trading above its fair value, placing it on InvestingPro’s "Most Overvalued" list.
